

17 June 2026

BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Code: 543064

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Symbol: COHANCE

Dear Sir/Madam,

Sub: Resignation of Whole-time Director and Chief Financial Officer of the Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), it is hereby informed that Mr. Himanshu Agarwal (DIN-06672915), Whole-time Director and Chief Financial Officer (Key Managerial Personnel) of the Company has tendered his resignation to pursue professional opportunity outside the organisation. Mr. Himanshu will be relieved from his duties with effect from the close of business hours on 13 September 2026.

In this regard the details as required under the SEBI Listing Regulations read with SEBI Master Circular dated 30 January 2026 and the resignation email dated 17 June 2026 as received from Mr. Himanshu are set out in Annexure A.

Kindly take the above on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

Sisir K. Mishra
Company Secretary & Compliance Officer

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Annexure A

Sl.	Disclosure requirements	Details
1	Reason for change viz. appointment, re appointment, resignation, removal, death or otherwise;	Resignation of Mr. Himanshu Agarwal (DIN-06672915), Whole-time Director and Chief Financial Officer (Key Managerial Personnel) of the Company
2	Date of appointment/re-appointment /cessation (as applicable) & term of appointment/re-appointment ;	Close of business hours on 13 September 2026
3	Brief profile (in case of appointment);	Not Applicable
4	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharastra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Resignation from the position of Whole Time Director, Chief Financial Officer (Key Managerial Personnel)

From Himanshu Agarwal [REDACTED]
Date Wed 6/17/2026 8:18 PM
To Umang Vohra [REDACTED]
Cc Sisir Mishra [REDACTED]; Gaurav Bahadur [REDACTED] >

Dear Mr Umang Vohra Chairman of the Board of Directors & CEO Cohance Lifesciences Limited

I am writing to formally resign from my positions as Whole Time Director, Chief Financial Officer and Key Managerial Personnel of Cohance Lifesciences Limited, as well as from the membership of any committees of the Board.

After a deeply rewarding tenure with the Company, I have decided to accept a new professional opportunity outside the organisation that aligns with my long-term career aspirations.

It has been an absolute privilege to lead the financial operations of Cohance during a period of such significant transformation. I am deeply grateful to the Board of Directors, the leadership team, and my colleagues in the finance department for their trust, support, and collaboration throughout my journey here. I am proud of the strong balance sheet, corporate governance standards and internal controls we have built together and have no doubt that the Company will continue its growth trajectory.

For the purposes of regulatory compliance and listing obligations, I hereby confirm that there are no other material reasons for my resignation other than the career advancement opportunity mentioned above.

My last working day will be the close of business hours on September 13, 2026, in accordance with the notice period applicable to my role. I am fully committed to ensuring an orderly and seamless handover of my responsibilities and to supporting the management in the smooth onboarding of my successor during my remaining time with the Company.

I request the Company to kindly accept my resignation. I wish Cohance, its Board, its leadership team and its shareholders continued success, prosperity, and growth in the years ahead.

Yours sincerely,

*Himanshu Agarwal
Whole Time Director & Chief Financial Officer of Cohance Lifesciences Limited*



Cohance Lifesciences Limited. Corp. Office
202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City,
TSIIC, Raidurg, Hyderabad - 500081, Telangana, India.
| www.cohance.com